Granted Patent B2

US 12,319,737 · App. 17/285,447 · Granted Jun 3, 2025

Inventors: Jeffrey S. Miller (Minneapolis, MN); Martin Felices (Minneapolis, MN); Daniel A. Vallera (Minneapolis, MN); Todd R. Lenvik (Minneapolis, MN)

Assignee: Regents of the University of Minnesota

C07K16/2851A61P35/00C07K16/283C07K16/30A61K2039/505C07K2317/22C07K2317/24C07K2317/622

Abstract

Claims (20)

1. An isolated amino acid sequence comprising SEQ ID NO:1.

2. An isolated DNA sequence encoding the amino acid sequence of SEQ ID NO: 1.

3. An isolated amino acid sequence comprising SEQ ID NO:2.

4. An isolated DNA sequence encoding the amino acid sequence of SEQ ID NO:2.

5. A compound comprising:

(i) a natural killer cell (NK) engaging domain;

(ii) an NK activating domain operably linked to the NK engaging domain; and

(iii) a targeting domain that selectively binds to a target cell and is operably linked to the NK activating domain and the NK engaging domain,

wherein the compound has an amino acid sequence comprising SEQ ID NO: 1 or SEQ ID NO: 2.

6. A composition comprising:

the compound of claim 5 ; and

a pharmaceutically acceptable carrier.

7. A method comprising: administering to a subject the compound of claim 5 in an amount effective to induce NK-mediated killing of a target cell, wherein the target cell expresses CLEC12A.

8. The method of claim 7 , wherein the target cell is a cancer cell.

9. A method for stimulating expansion of NK cells in vivo, the method comprising: administering to a subject an amount of the compound of claim 5 effective to stimulate expansion of NK cells in the subject.

10. A method of treating cancer in a subject, the method comprising: administering to the subject an amount of the compound of claim 5 effective for treating the cancer, wherein cells from the cancer express CLEC12A.

11. The method of claim 10 , wherein the cancer comprises prostate cancer, lung cancer, colon cancer, rectum cancer, urinary bladder cancer, melanoma, kidney cancer, renal cancer, oral cavity cancer, pharynx cancer, pancreas cancer, uterine cancer, thyroid cancer, skin cancer, head and neck cancer, cervical cancer, ovarian cancer, or hematopoietic cancer.

12. The method of claim 11 , further comprising administering the compound prior to, simultaneously with, or following chemotherapy, surgical resection of a tumor, or radiation therapy.

13. The method of claim 12 , wherein the chemotherapy comprises altretamine, amsacrine, L-asparaginase, colaspase, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytophosphane, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fluorouracil, fludarabine, fotemustine, ganciclovir, gemcitabine, hydroxyurea, idarubicin, ifosfamaide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitoxantrone, mitomycin C, nimustine, oxaliplatin, paclitaxel, pemetrexed, procarbazine, raltitrexed, temozolomide, teniposide, tioguanine, thiotepa, topotecan, vinblastine, vincristine, vindesine, and vinorelbine.

14. The method of claim 11 , wherein the hematopoietic cancer is AML.

Assignments (1)

Continuity (2)

References Cited (185)